Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva

Nidia Zapata, MD, associate professor, Instituto Nacional de Cancerologia, discusses the implications of the phase 3 VIALE-A trial (NCT02993523) of venetoclax (Venclexta) plus azacitidine (Vidaza) vs azacitidine alone in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for standard induction therapy.

Zapata: The results of the VIALE-A study…helped us understand the benefit of intensive treatment in patients with AML. This has led to a radical change in the treatment of these patients, as we now know that this combination allows patients who were not candidates for intensive chemotherapy to have a better quality of life and overall survival

In the long-term, this can lead to a dynamic improvement in the physical performance of patients who were initially not eligible for intensive treatment. [Venetoclax plus azacitidine] improved [patients’] quality of life [and] physical performance. [It] even makes them even candidates for reduced-intensity bone marrow transplantation, resulting in improved survival, quality of life, and overall benefit for these patients.

Editor's Note: Dr Zapata's transcript has been translated from Spanish to English.